Welcome to the 2-to-100 Club. This is a scan designed to find the biggest winners in the market, in the exact areas where they tend to emerge.
Yesterday we held our first members call, where I walked through the leading and emerging themes that excite me most in this universe.
The mounting bullish evidence in biotech is one of them.
Among the best signals in this space is when earlier-stage companies, the ones still in clinical trials, begin to outperform those with products already on the market.
It’s a clean way to gauge the market’s appetite for risk expanding within biotech. Here’s what I was talking about:
In a space with hundreds of stocks, for broad exposure, I’m buying the Biotech Clinical Trials ETF $BBC:
This is a primary trend reversal showing incredible relative strength right now.
Above 44, the risk is skewed to the upside, with a target of 62.75.
We also discussed a clinical-stage biotech completing a primary trend reversal. This one looks ready to go.
You need to have a subscription to access this content in full.
Log in or subscribe today to unlock new features and receive Member Benefits.
